Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Marizomib in newly diagnosed glioblastoma
NCT03345095Phase 3Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 3 trial of marizomib in glioblastoma (GBM), sponsored by European Organisation for Research and Treatment of Cancer. Started Jul 2018; status: completed.
02
Drugs
marizomib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03345095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03345095.